The Alzheimer’s Disease Drugs Market is undergoing a pivotal transformation. After decades marked by unsuccessful late-stage trials and high attrition rates, the period from 2023 to 2025 saw the first widely recognized successes in disease-modifying treatments (DMTs), reshaping both commercial and clinical perspectives. Regulatory approvals, coupled with aging populations, improved...